<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381144</url>
  </required_header>
  <id_info>
    <org_study_id>GB40223</org_study_id>
    <secondary_id>2017-003498-33</secondary_id>
    <nct_id>NCT03381144</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants</brief_title>
  <official_title>A Phase I, Randomised, Double-Blind, Placebo-Controlled, Single Centre, 3-Part, Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single-center, three-part study
      designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects
      of single and multiple ascending doses of GDC-0334 and the effect of food on the
      pharmacokinetics of GDC-0334 in healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2017</start_date>
  <completion_date type="Anticipated">September 5, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From signing of informed consent until 30 days after the last dose of study drug (Up to approximately 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Adverse Events, as Graded per the World Health Organization (WHO) Toxicity Grading Scale</measure>
    <time_frame>From signing of informed consent until 30 days after the last dose of study drug (Up to approximately 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Blood Pressure</measure>
    <time_frame>Up to approximately 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Heart Rate</measure>
    <time_frame>Up to approximately 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Up to approximately 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinical Laboratory Abnormalities</measure>
    <time_frame>Up to approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Physical Examination Abnormalities</measure>
    <time_frame>Up to approximately 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Neurological Examination Abnormalities</measure>
    <time_frame>Up to approximately 31 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS) - Part 3 Only</measure>
    <time_frame>Up to approximately 42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elapsed Time from Dosing at Which GDC-0334 is First Quantifiable in a Concentration versus Time profile (Tlag )</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 24 hours Post-dose (C24) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12 hours Post-dose (C12) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve from Time Zero to the Last Measurable Concentration (AUC0-t) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve from Time Zero Extrapolated to Infinity (AUC0-inf) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC0-inf Accounted for by Extrapolation to Infinity (AUC%extrap) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-Life (t1/2) for GDC-0334</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1: GDC-0334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GDC-0334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: GDC-0334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0334</intervention_name>
    <description>Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.</description>
    <arm_group_label>Part 1: GDC-0334</arm_group_label>
    <arm_group_label>Part 2: GDC-0334</arm_group_label>
    <arm_group_label>Part 3: GDC-0334</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive GDC-0334-matching placebo.</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_label>Part 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or non-pregnant, non-lactating healthy females. Females may be of
             non-childbearing potential or childbearing potential. Healthy females of childbearing
             potential must agree to use a highly effective method of contraception.

          -  Healthy males must agree to use an adequate method of contraception

          -  Body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m^2) or, if outside
             the range, considered not clinically significant by the investigator

          -  Must be willing and able to communicate and participate in the whole study

        Exclusion Criteria:

          -  Participants who have received any investigational medicinal product in a clinical
             research study within the previous 3 months

          -  Participants who are study site employees, or immediate family members of a study site
             or sponsor employee

          -  Participants who have previously been enrolled in this study. Participants who have
             enrolled in Part 1 are not permitted to enrol in Parts 2 or 3, and participants who
             have enrolled in Part 2 are not permitted to enroll in Part 3

          -  History of any drug or alcohol abuse in the past 2 years

          -  Regular alcohol consumption &gt;14 units per week (1 unit = ½ pint beer, 25 milliliters
             (mL) of 40% spirit or a 125-mL glass of wine)

          -  Current smokers and those who have smoked within the last 12 months. A breath carbon
             monoxide reading of greater than 6 parts per million (ppm) at screening or admission

          -  Current users of e-cigarettes and nicotine replacement products and those who have
             used these products within the last 12 months

          -  Participants who do not have suitable veins for multiple venepunctures/cannulation as
             assessed by the investigator at screening

          -  Clinically significant abnormal biochemistry, hematology or urinalysis as judged by
             the investigator

          -  Positive drugs-of-abuse test result at screening or admission

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or
             human immunodeficiency virus (HIV) results

          -  Evidence of renal impairment at screening, as indicated by an estimated creatinine
             clearance of &lt;70 milliliters per minute (mL/min) using the Cockcroft-Gault equation

          -  History of seizure

          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or gastrointestinal disease, or psychiatric disorder, as judged by the investigator

          -  Participants with a history of cholecystectomy or gall stones (applies to any regimen
             where food effect is being explored)

          -  History of serious adverse reaction or serious hypersensitivity to any drug or the
             formulation excipients

          -  Presence or history of active allergy requiring treatment, as judged by the
             investigator. History of hayfever is allowed unless it is active.

          -  Donation or loss of greater than 400 mL of blood within the previous 3 months

          -  Participants who are taking, or have taken, any prescribed or over-the-counter drug or
             herbal remedies in the 14 days or 5 half-lives, whichever is longer, before
             investigational medicinal product administration. Exceptions may apply on a
             case-by-case basis, if considered not to interfere with the objectives of the study,
             as agreed by the principal investigator and sponsor's medical monitor.

          -  History or presence of an abnormal electrocardiogram (ECG) that is clinically
             significant in the investigator's opinion, including complete left bundle branch
             block, second- or third-degree heart block, or evidence of prior myocardial
             infarction, at screening or admission

          -  QT interval corrected using Fridericia's formula (QTcF) &gt; 450 milliseconds (msec)
             demonstrated by at least two ECGs &gt;30 minutes apart

          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such
             as structural heart disease, coronary heart disease (symptomatic or with ischemia
             demonstrated by diagnostic testing), clinically significant electrolyte abnormalities,
             or family history of sudden unexplained death or long QT syndrome

          -  Current treatment with medications that are well known to prolong the QT interval

          -  History of dermatographism

          -  Presence or history of clinically significant skin disorders, as judged by the
             investigator (Parts 1 and 3 only)

          -  History of trauma or surgery (laceration repair is not excluded) to the arm but not
             including wrist or hand injury/surgery (Parts 1 and 3 only)

          -  Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID: GB40223 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Clinical Ltd, Clinical Research Unit</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

